NCT00409942

Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.

Prospective, Randomised, Open, Blinded-endpoint Study of Torasemide Prolonged Release vs Furosemide to Evaluate the Efficacy on Myocardial Fibrosis in Patients With Heart Failure

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 142 (actual)
• Sponsor: Ferrer Internacional S.A. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Torasemide is a loop diuretic (pyridine-sulfonylurea)with a wide experience in the treatment of oedema associated to heart failure, kidney or liver disease and either in the treatment of arterial hypertension (alone or combined with other anti-hypertensive drugs). It has been developed a new formulation of Torasemide (Torasemide prolonged release). The aim of this trial is to study the effects of Torasemide prolonged released in comparison with furosemide, in the reduction of myocardial fibrosis in patients with chronic heart failure (Class II-IV of the New York Heart Association Classification.

Conditions

• Congestive Heart Failure

Interventions

Type	Name	Description
DRUG	Torasemide Prolonged Release	Torasemide Prolonged release 10mg/day up to 40mg/day, treatment duration:8 months
DRUG	Furosemide	Furosemide 40mg/day up to 160mg/day, Treatment duration:8 months

Timeline

• Start date: 2007-03-01
• Primary completion: 2009-06-01
• Completion: 2009-06-01
• First posted: 2006-12-12
• Last updated: 2009-07-15

Locations

23 sites across 1 country: Spain